Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid carcinoma.

E Kebebew1

  • 1Department of Surgery, University of California, San Francisco, 513 Parnassus, S343, San Francisco, CA 94141-9918, USA. tron@itsa.ucsf.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.

Oncogene·2017
Same author

Neuroendocrine Tumor of the Pancreas as a Manifestation of Cowden Syndrome: A Case Report.

The Journal of clinical endocrinology and metabolism·2015
Same author

Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.

The Journal of clinical endocrinology and metabolism·2014
Same author

Functional thermogenic beige adipogenesis is inducible in human neck fat.

International journal of obesity (2005)·2013
Same author

KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome.

Endocrine-related cancer·2012
Same author

The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.

Endocrine-related cancer·2012
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Parathyroid carcinoma is a rare but challenging endocrine tumor. Early surgical intervention and reoperation for recurrent disease are crucial for managing hypercalcemia and improving patient outcomes.

Area of Science:

  • Endocrinology
  • Surgical Oncology

Background:

  • Parathyroid neoplasms are common, but parathyroid carcinoma is rare.
  • Diagnosis can be challenging, often presenting with severe hyperparathyroidism symptoms.

Purpose of the Study:

  • To review the diagnosis, treatment, and management of parathyroid carcinoma.
  • To highlight the importance of surgical resection and reoperation.

Main Methods:

  • Review of clinical presentation, diagnostic challenges, and treatment strategies for parathyroid carcinoma.
  • Discussion of surgical approaches, including en bloc resection and reoperation.
  • Evaluation of adjuvant therapies and medical management for hypercalcemia.

Main Results:

  • Parathyroid carcinoma often presents with profound hypercalcemia and elevated parathyroid hormone (PTH) levels.

Related Experiment Videos

  • Over 50% of patients experience persistent or recurrent disease.
  • Surgical resection is the primary treatment, with reoperation effective for recurrent disease.

    • Conclusions:

    • Optimal treatment involves en bloc resection with ipsilateral thyroid lobectomy.
    • Reoperation for localized recurrent parathyroid carcinoma can normalize calcium and PTH levels.
    • Chemotherapy, radiotherapy, bisphosphonates, and calcimimetics may help manage unresectable or recurrent disease but do not cure the tumor.